# The Partner Choice, Not the Drug, Sank ORIC's Stock

- slug: the-partner-choice-not-the-drug-sank-orics-stock
- date: 2026-04-01
- category: Biotech & Life Sciences

ORIC picked a sensible dose for its prostate cancer drug. The market dropped the stock 27% because the real question is why the company chose darolutamide as its combination partner — and what Pfizer found with a similar drug first.

---